Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients
Status:
WITHDRAWN
Trial end date:
2025-04-24
Target enrollment:
Participant gender:
Summary
This phase IV trial compares suvorexant with standard of care to standard of care alone for improving difficulty sleeping (insomnia) and reducing confusion (delirium) in hospitalized cancer patients. Delirium can lengthen hospitalization, increase the delay of cancer treatment and can even increase the risk of premature death. Suvorexant is in a class of medications called orexin receptor antagonists. It works by blocking the action of a certain natural substance in the brain that causes wakefulness. Giving suvorexant with standard of care to treat insomnia may be more effective compared to standard of care alone in reducing the development of delirium in hospitalized cancer patients.
Phase:
PHASE4
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Interviews as Topic Practice Guidelines as Topic Standard of Care suvorexant